3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
19
Endometrial Neoplasms
14
Ovarian Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
7
Squamous Cell Carcinoma of Head and Neck
6
Uterine Cervical Neoplasms
5
Head and Neck Neoplasms
5
Breast Neoplasms
5
Rectal Neoplasms
4
Pancreatic Neoplasms
4
Melanoma
4
Lung Neoplasms
4
Colonic Neoplasms
4
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Osteosarcoma
2
Multiple Myeloma
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Interventions
Gemcitabine
92
Cisplatin
70
Oxaliplatin
37
Capecitabine
37
durvalumab
29
Fluorouracil
26
pembrolizumab
24
Leucovorin
22
S 1 (combination)
18
Nivolumab
13
Irinotecan
13
Bevacizumab
13
lenvatinib
12
tremelimumab
10
apatinib
8
Trastuzumab
7
Injections
7
Albumin-Bound Paclitaxel
7
130-nm albumin-bound paclitaxel
7
Paclitaxel
6
Immune Checkpoint Inhibitors
6
Docetaxel
6
titanium silicide
5
surufatinib
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Biliary Tract Neoplasms
×
dostarlimab
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled